IL-10 polymorphisms and prostate cancer risk: A meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 2, 2011, Pages 129-135

  Shao, N ^a   Xu, B ^a   Mi, Y Y ^a   Hua, L X ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

IL 10; meta analysis; polymorphism

Indexed keywords

ADENINE; CYTOSINE; GUANINE; THYMINE;

ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ACTIVITY; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; INTERLEUKIN 10 GENE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

EID: 79956062198     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.6     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-130
2. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 (Spec 1): 103-121
3. Bosland MC. The role of steroid hormones in prostate carcinogenesis. JNatl Cancer Inst Monogr 2000; 27): 39-66
4. Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ et al. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 2010; 202: 76-81
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85 (Pubitemid 30451850)
6. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60): 78-83 (Pubitemid 34722951)
7. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14 (11 Part 1): 2563-2568 (Pubitemid 41752716)
8. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL-10 gene and further characterisation of the 5 0flanking sequence. Immunogenetics 1997; 46: 120-128 (Pubitemid 27234709)
9. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. World J Urol 2008; 19: 119-124
10. Crawley E, Woo P, Isenberg DA. Single nucleotide polymorphic haplotypes of the interleukin-10 5 0flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2017-2018 (Pubitemid 30257777)
11. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8 (Pubitemid 27050850)
12. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201 (Pubitemid 36531795)
13. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 2005; 173: 709-712 (Pubitemid 40239324)
14. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother 2007; 56: 371-379 (Pubitemid 46035905)
15. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006; 5: 143-149 (Pubitemid 43824470)
16. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED et al. Genetic polymorphisms of interleukin-1B (IL- 1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525-4530
17. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372 (Pubitemid 34651380)
18. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC et al. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 2007; 43: 472-475 (Pubitemid 46177585)
19. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008; 29: 573-578 (Pubitemid 351404874)
20. Omrani MD, Bazargani S, Bageri M. Interlukin-10, interferon-g and tumor necrosis factor-a genes variation in prostate cancer and benign prostatic hyperplasia. Curr Urol 2009; 2: 175-180
21. Wang MH, Helzlsouer KJ, Smith MW, HoffmanBolton JA, Clipp SL, Grinberg V et al. Association of IL10 and other immune response-and obesity-related genes with prostate cancer in CLUE II. Prostate 2009; 69: 874-885
22. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN et al. IL-10 1082 G4A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009; 27: 389-396
23. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 2010; 70: 341-352
24. Liu J, Song B, Bai X, Liu W, Li Z, Wang J et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010; 10: 456
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188 (Pubitemid 17189972)
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748
27. Barba M, Yang L, Schunemann HJ, Sperati F, Grioni S, Stranges S et al. Urinary estrogen metabolites and prostate cancer: a casecontrol study and meta-analysis. J Exp Clin Cancer Res 2009; 28: 135
28. Ahirwar D, Mandhani A, Mittal RD. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res 2009; 40: 97-102
29. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2: 25-31 (Pubitemid 33674866)
30. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX et al. Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1525-1532
31. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006; 176: 1012-1016 (Pubitemid 44142579)
32. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO et al. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 2009; 30: 1358-1362
33. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-956 (Pubitemid 34988382)
34. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY. Berberine suppresses inflammatory agents-induced interleukin-1b and tumor necrosis factor-a productions via the inhibition of IkB degradation in human lung cells. Pharmacol Res 2007; 56: 193-201
35. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23: 3526-3535
36. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-827
37. ElsasserBeile U, Kolble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Biol 1998; 19: 470-476 (Pubitemid 28539329)
38. Richardsen E, Uglehus RD, Due J, Busch C, Busund LT. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-b, IL-10 and Ki67. Cancer Epidemiol 2010; 34: 316-322
39. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279: 281-286
40. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-378
41. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-872